Recombinant lipoprotein-based immunotherapy against human papillomavirus-associated cancer

Company Name: National Health Research Institutes Contact Person: Ruby Weng Tel: +886-37-246-166 ext. 33211 E-mail: rubyweng@nhri.org.tw Address: 35 Keyan Road, Zhunan, Miaoli County 35053,Taiwan Website: http://www.nhri.org.tw/



Incidence of HPV associated cancer



Current prophylactic HPV vaccines: Gardasil®, Cervarix®, Gardasil-9®



Therapeutic HPV vaccine may prevent the progress of HPV infection to cancer development



Protective mechanisms of prophylactic and therapeutic HPV vaccines



Shen et al. Infect. Control. J., 2012

Approaches of therapeutic HPV vaccine

- DNA Vaccines
- Viral vectors or bacterial vectors
- Dendritic cell-based vaccines
- Subunit vaccines (high safety profile)
- Long peptide containing CTL epitopes
- Whole protein

Peptide/protein-based (Low immunogenicity)





Co-delivery of immunostimulatory adjuvant and antigen



Anti-tumor effects of rlipo-E7m in two model



Combination of chemotherapy inhibited large tumor growth



NOLY RESEARC

Chang et al. Oncoimmunology, 2016

Summary

- 1. The therapeutic HPV vaccine (rlipo-E7m) could be used to treat HPV-associated cancer that includes cervical cancer and oropharynx cancer.
- 2. Combination of chemotherapy dramatically increase anti-tumor effects of rlipo-E7m/CpG.
- 3. The therapeutic HPV vaccine is safe, efficient and low cost.

